Androgen-deprivation Therapy in Prostate Cancer and Cardiovascular Risk: a Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology

Overview

Journal CA Cancer J Clin

Publisher Wiley

Specialty Oncology

Date 2010 Feb 4

PMID 20124400

Citations 69

Authors

Glenn N Levine

Anthony V DAmico

Peter Berger

Peter E Clark

Robert H Eckel

Nancy L Keating

Richard V Milani

Arthur I Sagalowsky

Matthew R Smith

Neil Zakai

Affiliations

Soon will be listed here.

Citing Articles

[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].

Klemm J, von Deimling M, Fisch M, Kramer G, Tilki D, Steuber T Urologie. 2023; 63(3):262-268.

PMID: 37874334 DOI: 10.1007/s00120-023-02222-1.

Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.

Yan Z, Xu Y, Li K, Liu L Medicine (Baltimore). 2023; 102(39):e34690.

PMID: 37773823 PMC: 10545124. DOI: 10.1097/MD.0000000000034690.

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China.

Chen L, Lu F, Wang Z, Chen H, Chen M, Peng C Hum Vaccin Immunother. 2023; 19(2):2225389.

PMID: 37350143 PMC: 10332218. DOI: 10.1080/21645515.2023.2225389.

Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.

Braga-Basaria M, Travison T, Taplin M, Lin A, Dufour A, Habtemariam D PLoS One. 2023; 18(2):e0281508.

PMID: 36763576 PMC: 9916640. DOI: 10.1371/journal.pone.0281508.

Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China.

Zhang F, Li M, Li X, Bai H, Gao J, Liu H BMC Public Health. 2022; 22(1):2269.

PMID: 36471351 PMC: 9721084. DOI: 10.1186/s12889-022-14718-0.

References

Smith M, Lee H, Fallon M, Nathan D . Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008; 71(2):318-22. PMC: 2614378. DOI: 10.1016/j.urology.2007.08.035. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008; 31 Suppl 1:S55-60. DOI: 10.2337/dc08-S055. View

Smith M . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004; 63(4):742-5. DOI: 10.1016/j.urology.2003.10.063. View

Pyorala M, Miettinen H, Laakso M, Pyorala K . Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998; 98(5):398-404. DOI: 10.1161/01.cir.98.5.398. View

Efstathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H . Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2008; 27(1):92-9. PMC: 2645096. DOI: 10.1200/JCO.2007.12.3752. View

Paulson D . Management of metastatic prostatic cancer. Urology. 1985; 25(2 Suppl):49-52. View

Braga-Basaria M, Dobs A, Muller D, Carducci M, John M, Egan J . Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24(24):3979-83. DOI: 10.1200/JCO.2006.05.9741. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

Nanda A, Chen M, Braccioforte M, Moran B, DAmico A . Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302(8):866-73. DOI: 10.1001/jama.2009.1137. View

10.

Lee H, McGovern K, Finkelstein J, Smith M . Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005; 104(8):1633-7. DOI: 10.1002/cncr.21381. View

11.

DAmico A, Chen M, Renshaw A, Loffredo M, Kantoff P . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3):289-95. DOI: 10.1001/jama.299.3.289. View

12.

Saigal C, Gore J, Krupski T, Hanley J, Schonlau M, Litwin M . Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110(7):1493-500. DOI: 10.1002/cncr.22933. View

13.

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

14.

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

15.

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

16.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

17.

DAmico A, Denham J, Crook J, Chen M, Goldhaber S, Lamb D . Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25(17):2420-5. DOI: 10.1200/JCO.2006.09.3369. View

18.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

19.

Tsai H, DAmico A, Sadetsky N, Chen M, Carroll P . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99(20):1516-24. DOI: 10.1093/jnci/djm168. View

20.

Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H . Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26(15):2497-504. DOI: 10.1200/JCO.2007.14.9021. View